Get the Stockscreener App
1.74
3.57%
0.06
After Hours:
1.75
0.01
+0.57%
Inovio Pharmaceuticals Inc stock is traded at $1.74, with a volume of 581.96K.
It is up +3.57% in the last 24 hours and up +4.82% over the past month.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
See More
Previous Close:
$1.68
Open:
$1.69
24h Volume:
581.96K
Relative Volume:
0.42
Market Cap:
$119.54M
Revenue:
$832.00K
Net Income/Loss:
$-135.12M
P/E Ratio:
-0.2857
EPS:
-6.09
Net Cash Flow:
$-124.69M
1W Performance:
-3.87%
1M Performance:
+4.82%
6M Performance:
-37.63%
1Y Performance:
-11.22%
1-Day Range:
$1.68
$1.77
1-Week Range:
$1.65
$1.7987
52-Week Range:
$1.30
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.74 | 115.42M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.69 | 117.06B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.86 | 80.87B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
717.80 | 45.06B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.66 | 42.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
301.12 | 32.42B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - BioSpace
Robbins LLP Urges INO Stockholders Who Lost Money Investing in Inovio Pharmaceuticals, Inc. to ... - Caledonian Record
Robbins LLP Urges INO Stockholders Who Lost Money Investing - GlobeNewswire
INO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DEADLINE ALERT for TCPC, ORCL, PSFE, and INO: The Law - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Inovio - GlobeNewswire
Inovio, Akeso announce clinical collaboration - TipRanks
Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire
LEVI & KORSINSKY, LLP: INO SHARES DECLINE 24% AS FDA REVIEW CLAS - GuruFocus
UPCOMING DEADLINE: Inovio Pharmaceuticals (INO) Securities - GlobeNewswire
LEVI & KORSINSKY, LLP: INO SHARES DECLINE 24% AS FDA REVIEW CLASSIFICATION REVEALS ALLEGED REGULATORY SETBACK - Finviz
LEVI & KORSINSKY, LLP: INO SHARES DECLINE 24% AS FDA REVIEW CLASSIFICATION REVEALS ALLEGED REGULATORY SETBACK (2026-03-04) - Seeking Alpha
Inovio (INO) Teams Up with Akeso for Groundbreaking Cancer Thera - GuruFocus
INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) - Financial Times
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Inovio - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc.and Certain Officers – INO - GlobeNewswire Inc.
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Inovio Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2026 to Discuss Your RightsINO - PR Newswire
Can Inovio Pharmaceuticals Inc. be recession proofJuly 2025 Setups & Free Daily Entry Point Trade Alerts - mfd.ru
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Levi & Korsinsky, LLP: FDA Accelerated Approval Eligibility Challenged in Inovio Pharmaceuticals Securities Action - GlobeNewswire
INOInovio Pharmaceuticals Reports 2014 Fourth Quarter and Year End Financial Results - ADVFN Ltd
Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Barchart.com
Portnoy Law Firm Announces Class Action on Behalf of Inovio Pharmaceuticals, Inc. Investors - GlobeNewswire
2026-03-01 | INO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:INO | Press Release - Stockhouse
INOVIO PHARMACEUTICALS, INC. reports annual 15,000 glioblastoma diagnoses as demand for new treatments rises - Traders Union
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Inovio - GlobeNewswire
INOVIO (NASDAQ: INO) CSO logs RSU exercises and tax share withholding - Stock Titan
INOVIO (INO) CFO reports RSU vesting and tax-withholding share dispositions - Stock Titan
RSUs vest and tax shares withheld for Inovio (NASDAQ: INO) CEO - Stock Titan
Inovio Pharmaceuticals (INO) CMO settles RSUs, reports tax share withholding - Stock Titan
Director converts RSUs into 972 INOVIO (NASDAQ: INO) shares - Stock Titan
INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 - Barchart.com
Inovio Pharmaceuticals, Inc. Stock Alert: INO Stockholders Who Lost Money in the Company Should Contact Robbins LLP for Information on How to Recover Their Losses - The Malaysian Reserve
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit - Barchart.com
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Inovio ... - Bluefield Daily Telegraph
The Gross Law Firm Announces the Filing of a Securities - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain OfficersINO - PR Newswire
Inovio Pharmaceuticals, Inc. Stock Alert: INO Stockholders Who L - GuruFocus
Inovio Pharmaceuticals Spotlights INO-3107 BLA Acceptance, FDA Talks Ahead of Oct. 30 PDUFA Date - MarketBeat
Inovio Pharmaceuticals Faces Investor Lawsuit After FDA Review Setback and Stock Drop - TipRanks
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Faruqi & Faruqi Investigates Potential Claims Against Inovio - Intellectia AI
INO CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 - marketscreener.com
INO CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Inovio - GlobeNewswire
Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money H - GuruFocus
INO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
LEVI & KORSINSKY, LLP: CELLECTRA DEVICE MANUFACTURING PRACTICES AT CENTER OF INOVIO PHARMACEUTICALS SECURITIES LITIGATION - TipRanks
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
2.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):